© APA Juhasz
Following two and a half years of construction, the company opened a new research and development center offering modern and secure jobs to more than 100 highly qualified employees at a cost of EUR 23.5 million. As a result, Octapharma strengthened Vienna’s status as a Group-wide center for research and development. In addition, construction work will be completed this year on a new pilot plant located at the site. This production line comprises the link between research work and routine production. Investments in the pilot plant amount to EUR 39.5 million. Simultaneously with the opening of the R&D center, Octapharma carried out the groundbreaking ceremony for its third major investment, namely a new production building involving investments of EUR 79 million. It will enable a doubling of production capacities by the year 2026. Total investments for all three projects amount to EUR 142 million.
“With these investments we profess our commitment to the Vienna business location, with which we are linked by a long tradition. In addition to the R&D center, one of the most modern production plants in the world will be built, thus creating many high-quality jobs”, explains Barbara Rangetiner, General Manager of Octapharma Pharmazeutika. The company, which has been operating in Vienna since 1989, specializes in the development and manufacturing of products derived from human proteins, and is the world’s largest family-owned supplier in this field.
